Such mutations may render the cancer cells vulnerable to modulators of the core splicing machinery, as suggested by experiments showing that H3B-8800, a recently described modulator of SF3B1, preferentially kills cancer cells with mutations in spliceosomal components. This evidence concerns the gene SF3B1 and cancer.